Court Upholds FTC Order Against POM, But Scrutinizes Clinical Trial Requirement
This article was originally published in The Tan Sheet
Executive Summary
The U.S. Court of Appeals for the District of Columbia Circuit on Jan. 30 issued a ruling largely upholding the FTC’s 2012 order against POM, but said the agency’s argument fails “scrutiny insofar as it categorically requires two RCTs for all disease-related claims.”